CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.122
EU - Europa 5.833
AS - Asia 3.948
SA - Sud America 614
AF - Africa 323
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 18.854
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.894
DE - Germania 2.175
CN - Cina 1.220
SG - Singapore 1.206
IT - Italia 1.077
SE - Svezia 830
HK - Hong Kong 709
GB - Regno Unito 561
BR - Brasile 497
BG - Bulgaria 272
AT - Austria 232
RU - Federazione Russa 205
VN - Vietnam 176
CA - Canada 172
TR - Turchia 153
CI - Costa d'Avorio 146
FI - Finlandia 113
IN - India 111
SN - Senegal 104
FR - Francia 80
KR - Corea 80
UA - Ucraina 76
JP - Giappone 74
AR - Argentina 40
BD - Bangladesh 38
MX - Messico 35
CH - Svizzera 33
NL - Olanda 29
MA - Marocco 28
PL - Polonia 28
IQ - Iraq 24
BE - Belgio 23
ZA - Sudafrica 20
ES - Italia 19
IR - Iran 19
VE - Venezuela 17
PK - Pakistan 16
ID - Indonesia 15
CO - Colombia 14
EC - Ecuador 14
PH - Filippine 14
SA - Arabia Saudita 14
LT - Lituania 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 11
AU - Australia 10
IE - Irlanda 10
IL - Israele 10
UY - Uruguay 9
AZ - Azerbaigian 8
MY - Malesia 8
TW - Taiwan 8
PE - Perù 7
SK - Slovacchia (Repubblica Slovacca) 7
CL - Cile 6
EE - Estonia 6
EG - Egitto 5
GR - Grecia 5
HU - Ungheria 5
JM - Giamaica 5
JO - Giordania 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
DZ - Algeria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
RO - Romania 4
RS - Serbia 4
TN - Tunisia 4
AL - Albania 3
KE - Kenya 3
LB - Libano 3
NG - Nigeria 3
PT - Portogallo 3
BJ - Benin 2
BY - Bielorussia 2
BZ - Belize 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GT - Guatemala 2
PA - Panama 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
AO - Angola 1
BH - Bahrain 1
CR - Costa Rica 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 18.843
Salva come PNG Salva come JPEG
Città #
Ashburn 1.020
Dallas 745
Hong Kong 692
Singapore 677
Woodbridge 658
Chandler 580
Santa Clara 541
Fairfield 490
Ann Arbor 403
Milan 359
Houston 314
Beijing 282
Sofia 271
Shanghai 262
New York 252
Seattle 217
Vienna 211
Wilmington 209
Cambridge 182
Los Angeles 162
Abidjan 146
London 139
Princeton 138
Boardman 136
Ottawa 109
Lawrence 106
Munich 106
Dakar 104
Florence 94
Jacksonville 91
Hefei 90
Frankfurt am Main 89
Serra 87
Medford 80
Seoul 74
Pisa 60
Rome 60
Nanjing 59
Izmir 57
Tokyo 56
Istanbul 55
Bremen 52
Dearborn 52
Des Moines 51
Redondo Beach 51
Boulder 50
Dong Ket 49
São Paulo 40
Buffalo 39
San Diego 39
Fuzhou 34
Redmond 34
Turku 29
Lancaster 28
Bern 27
Düsseldorf 25
Helsinki 25
Ho Chi Minh City 25
Redwood City 25
Ogden 24
Brussels 22
Denver 21
Hanoi 21
Montreal 21
Guangzhou 20
Nanchang 20
Rio de Janeiro 20
Washington 20
Phoenix 19
Quanzhou 18
Toronto 18
Belo Horizonte 17
Brooklyn 17
Casablanca 17
Council Bluffs 17
Jiaxing 16
Kunming 16
Warsaw 16
Chicago 15
Nuremberg 15
San Francisco 15
Changsha 14
Orem 14
Stockholm 14
Zhengzhou 14
Atlanta 13
Boston 13
Chengdu 13
Columbus 13
Jüchen 13
Pune 13
Baghdad 12
Poplar 12
Brasília 11
Johannesburg 11
Ningbo 11
Norwalk 11
Shenyang 11
Tashkent 11
Wuhan 11
Totale 11.778
Salva come PNG Salva come JPEG
Nome #
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 277
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 268
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 241
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 240
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 235
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 234
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 233
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 229
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 223
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 220
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 218
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 217
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 213
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 212
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 211
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 208
Targeted Therapy in Thyroid Cancer: State of the Art 208
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 204
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 203
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 202
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 199
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 199
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 196
RET point mutations in Thyroid Carcinoma 195
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 195
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 189
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 187
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 184
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 184
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 182
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 181
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 180
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 178
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 175
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 175
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 173
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 172
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 171
Il carcinoma tiroideo: nuove prospettive terapeutiche. 171
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 171
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 170
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 167
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 166
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 165
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 161
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 160
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 160
Thyroid consequences of the Chernobyl nuclear accident. 158
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 157
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 157
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 156
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 156
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 154
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 152
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 151
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 151
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 150
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 150
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 150
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 149
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 148
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 148
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 147
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 146
null 146
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 146
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 143
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 142
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 142
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 141
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 140
Thyroid incidentaloma 139
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 138
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 138
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 137
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 137
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 135
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 133
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 133
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 132
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 131
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 127
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 127
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 126
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 124
null 122
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 120
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 118
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 118
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 115
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 115
null 114
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 112
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 112
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 111
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 111
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 110
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 109
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 109
null 107
Totale 16.442
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.627
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.627
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021499 0 0 0 0 0 84 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.598 161 174 220 110 214 283 114 52 28 22 70 150
2024/20254.314 47 154 43 267 483 424 303 218 467 539 422 947
2025/20262.956 405 774 587 470 567 153 0 0 0 0 0 0
Totale 19.112